Finerenone and its role in diabetic kidney disease state of the art

• María Raad Sarabia ^[2] ; Rodrigo Daza Arnedo ^[1] ; Jorge Rico Fontalvo ^[1] ; Nataly Aguilar Salcedo ^[1] ; Mercedes Alfaro ^[1] ; Diana Navas Torrejano ^[1] ; María X. Cardona Blanco ^[1] ; Isabela Uparella Gulfo ^[1] ; Emilio Abuabara Franco ^[1]
  1. [1] Annamalai University

     Annamalai University

     India

     
  2. [2] Department of Internal Medicine, University of Sinu, Cartagena, Colombia
• Localización: Archivos de medicina, ISSN-e 1698-9465, Vol. 18, Nº. 1, 2022
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Diabetic kidney disease represents the leading cause of endstage kidney disease and its presence directly impacts cardiovascular risk and mortality in individuals with diabetes mellitus. Since albuminuria is the main marker of DKD, its reduction has been established in recent years as one of the therapeutic objectivesto impact the evolution of the disease. Finerenone, a mineralocorticoid receptor antagonist, has been described in several recent studies as a drug whose mechanism of action could contribute to reducing the progression of DKD, reducing the progression of eGFR and albuminuria with an adequate profile of safety in patients with all stages of kidney disease.